Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Income Statement [Abstract]
License revenue	$ 20,376	$ 0
Operating expenses:
Research and development	47,956	11,408
Acquisition of in-process research and development	15,480	12,020
General and administrative	92,745	80,734
Total operating expenses	156,181	104,162
Loss from operations	(135,805)	(104,162)
Other income (expense), net:
Interest income	205	71
Change in fair value of contingent consideration liability - related parties	173	(1,133)
Change in fair value of short term notes receivable - related party		718
Change in fair value of convertible promissory notes	0	16,974
Change in fair value of derivative liability	41	150
Change in fair value of warrant liability	(87)
Unrealized loss on other investments held at fair value	(12,346)
Unrealized gain on other investments		19,856
Loss on conversion of convertible promissory notes	(513)
Loss on asset acquisition of a variable interest entity	0	(504)
Gain on consolidation of a variable interest entity	3,543
Foreign exchange gain (loss), net	8,481	(194)
Other income (expense), net	(293)	359
Total other income (expense), net	(796)	2,349
Total loss before income taxes	(136,601)	(101,813)
Benefit from (provision for) income taxes	3,989	(305)
Gain on dilution of equity method investment, net of tax	16,923
Losses from investments in equity method investees, net of tax	(58,555)	(76,507)
Net loss	(174,244)	(178,625)
Net income (loss) attributable to redeemable noncontrolling interests and noncontrolling interests	(6,436)	(8,782)
Net loss attributable to ATAI Life Sciences N.V. stockholders	$ (167,808)	$ (169,843)
Net loss per share attributable to ATAI Life Sciences N.V. stockholders — basic and diluted	$ (1.21)	$ (1.83)
Weighted average common shares outstanding attributable to ATAI Life Sciences N.V. stockholders — basic and diluted	138,265,859	93,019,072